Kochi, India

Spinvin Venugopal


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Spinvin Venugopal: Innovator in Chroman Compounds

Introduction

Spinvin Venugopal is a notable inventor based in Kochi, India. He has made significant contributions to the field of chemistry, particularly in the synthesis of chroman compounds. His innovative approach has led to advancements that are both economically scalable and environmentally friendly.

Latest Patents

Venugopal holds a patent for a process titled "Process for preparing chroman compounds." This patent describes a method for manufacturing substituted chroman compounds without the use of pyrophoric reagents. The process also includes synthesis routes that eliminate the need for column chromatography purification steps. Notably, the patent relates to the synthesis of a Calcium sensing receptor (CaSR) modulating agent, specifically 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, along with its intermediates and pharmaceutically acceptable salts. Venugopal's work is encapsulated in 1 patent.

Career Highlights

Venugopal is currently associated with Lupin, Inc., a prominent pharmaceutical company. His role involves research and development in the synthesis of novel compounds that have potential therapeutic applications. His expertise in the field has positioned him as a valuable asset to his team and the company.

Collaborations

Some of his notable coworkers include Rajender Kumar Kamboj and Shaji George Kochumalayil. Their collaborative efforts contribute to the innovative environment at Lupin, Inc., fostering advancements in pharmaceutical research.

Conclusion

Spinvin Venugopal's contributions to the field of chemistry, particularly in the synthesis of chroman compounds, highlight his innovative spirit and dedication to advancing pharmaceutical science. His work not only enhances the efficiency of chemical processes but also opens new avenues for therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…